Digestive Health

Patients experiencing IBS were more likely to self-report a non-celiac gluten sensitivity.

A deep dive for pharmacists into this frequently debilitating disorder

Migraine is highly prevalent in people living with IBS.

Tremfaya is a combination of guselkumab and golimumab.

Resmetirom also has potential as a treatment for NASH.

A clinical trial looks into whether the use of open-label placebos can lead to better outcomes for children and teenagers with functional abdominal pain or irritable bowel syndrome.

Many pediatric opioid prescriptions are high risk and leave children at risk of overdose and side effects like constipation.

A meta-analysis in JAMA Pediatrics looks at whether vaccines can prevent rotavirus gastroenteritis.

A study published in The BMJ revealed a link between ultra-processed foods and a higher risk of IBD.

The results of a new study show that constipation prevalence was 2- to 3-fold higher in pregnant women and women postpartum.

What pharmacists should know about constipation.

Individuals with irritable bowel syndrome with constipation indicated that although their symptoms worsened during the pandemic, they did not seek medical care.

We talked to 2 pharmacists to see how they address the most common questions around constipation.

Pharmacists can play an important role in educating patients about the best options for managing constipation.

When counseling a patient with constipation, it is important to review the patient’s medication list to determine the potential cause.

Pharmacists must keep up to date with the latest in irritable bowel syndrome management.

Vibegron (Gemtesa; Sumitovant Biopharma) 75 mg tablets are indicated to treat patients with an overactive bladder.

The Drug Topics® team rounded up some of our top-read articles from the last year.

Pharmacists can counsel patients on how to best manage heartburn and GERD symptoms.

Recent research offers insight into the global prevalence of gastrointestinal disorders.

Regular use of proton pump inhibitors could increase the risk of developing diabetes, but the findings are based off an observational study.

Results of 2 recent studies suggested a higher risk of developing osteoporosis in patients with inflammatory bowel disease.

The sodium sulfate, magnesium sulfate, and potassium chloride tablet gives patients an alternative to liquid-based colonoscopy preparations.

Eli Lilly reported new efficacy and safety data for mirikizumab in moderate-to-severe Crohn disease.

An altered composition of the gut microbiota might play a role in major depressive disorder and affect treatment response.

Results of the phase 2b study showed that, in its highest-dosing arm, 21% of patients with left-sided ulcerative colitis were in clinical remission.

Higher cumulative exposure to systemic antibiotic therapy may be associated with a greater risk of new-onset inflammatory bowel disease.

The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.

What supplements are patients looking for the most, and how can pharmacists help?